SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 09/27/2024 at 15:35, 1 year 4 months ago

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
US FDA approves Dupixent as the first-ever biologic medicine for COPD, based on phase 3 studies showing significant reduction in exacerbations and improved lung function. Dupixent is now leading in new-to-brand prescriptions for FDA-approved indications

FDA Approval Dupixent COPD Treatment Biologic Medicine Phase 3 Studies
PRESS RELEASE

published on 09/27/2024 at 15:35, 1 year 4 months ago

Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO
La FDA approuve Dupixent comme premier médicament biologique pour la BPCO aux États-Unis, offrant un nouveau traitement aux patients inadéquatement contrôlés. Résultats positifs des études BOREAS et NOTUS

FDA Traitement Études BPCO Dupixent
BRIEF

published on 09/27/2024 at 13:05, 1 year 4 months ago

Dupixent Authorized in China as First Biologic Medicine for COPD Patients

China Approval COPD Dupixent Biologic Medicine
BRIEF

published on 09/27/2024 at 13:05, 1 year 4 months ago

Dupixent autorisé en Chine comme premier médicament biologique pour les patients atteints de BPCO

Chine MPoC Approbation Dupixent Médecine Biologique
PRESS RELEASE

published on 09/27/2024 at 13:00, 1 year 4 months ago

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Dupixent approved in China as the first-ever biologic medicine for COPD patients, following landmark phase 3 studies. Approval crucial for addressing COPD burden in China

China COPD Dupixent Biologic Medicine Phase 3 Studies
PRESS RELEASE

published on 09/27/2024 at 13:00, 1 year 4 months ago

Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO
Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO, réduit les exacerbations et améliore la fonction respiratoire. Approbation suite à études de phase III

Traitement Chine Approbation BPCO Dupixent
BRIEF

published on 09/21/2024 at 00:41, 1 year 4 months ago

Approbation du Sarclisa aux États-Unis pour le traitement du myélome multiple

FDA Sanofi Myélome Multiple Sarclisa Traitement De Première Ligne
BRIEF

published on 09/21/2024 at 00:41, 1 year 4 months ago

Sarclisa Approved in the United States for the Treatment of Multiple Myeloma

FDA Sanofi Multiple Myeloma Sarclisa First Line Treatment
PRESS RELEASE

published on 09/21/2024 at 00:36, 1 year 4 months ago

Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)
La FDA approuve le Sarclisa aux États-Unis en association avec un traitement conventionnel pour les patients atteints de myélome multiple nouvellement diagnostiqué, non éligibles à une transplantation. Sanofi comble un vide thérapeutique important

FDA Traitement Sanofi Myélome Multiple Sarclisa
BRIEF

published on 09/20/2024 at 13:50, 1 year 4 months ago

Le CHMP recommande l'approbation du Dupixent pour les enfants de 12 mois et plus

Médicament Dupixent Enfants CHMP Œsophagite

Published on 02/02/2026 at 00:05, 11 hours 57 minutes ago

Resource Upgrade Drilling Begins on Challenger Open Pits
Published on 01/31/2026 at 03:15, 2 days 8 hours ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 2 days 9 hours ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 2 days 10 hours ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 2 days 12 hours ago

BE Resources Announces Private Placement

View all ACCESSWIRE

Published on 02/02/2026 at 11:58, 4 minutes ago

Aperam celebrates 15 years of value creation
Published on 02/02/2026 at 11:58, 4 minutes ago

Aperam celebrates 15 years of value creation
Published on 02/02/2026 at 10:48, 1 hour 14 minutes ago

EQS-Adhoc: GRAMMER AG exceeds earnings forecast for the 2025 financial year – operating EBIT in Q4 significantly above previous year's level
Published on 02/02/2026 at 10:30, 1 hour 32 minutes ago

News Release
Published on 02/02/2026 at 10:29, 1 hour 33 minutes ago

Rieter Completes Acquisition of Barmag

View all EQS

Published on 02/02/2026 at 08:45, 3 hours 17 minutes ago

BAIKOWSKI: Business growth in 2025
Published on 02/02/2026 at 08:45, 3 hours 17 minutes ago

BAIKOWSKI : Croissance de l’activité en 2025
Published on 02/02/2026 at 07:00, 5 hours 2 minutes ago

Entech signe un contrat avec TotalEnergies pour la construction d’un système de stockage hybride éolien de 8MW/8MWh en Guadeloupe
Published on 01/30/2026 at 18:40, 2 days 17 hours ago

ICADE - Bilan semestriel du contrat de liquidite
Published on 01/30/2026 at 18:01, 2 days 18 hours ago

Emova Group - Résultats annuels 2024/25

View all LES ECHOS COMFI WIRE

News